1. Home
  2. STRO vs GLQ Comparison

STRO vs GLQ Comparison

Compare STRO & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

N/A

Current Price

$8.76

Market Cap

159.5M

Sector

Health Care

ML Signal

N/A

Logo Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

GLQ

Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

N/A

Current Price

$7.07

Market Cap

142.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
STRO
GLQ
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
142.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STRO
GLQ
Price
$8.76
$7.07
Analyst Decision
Strong Buy
Analyst Count
14
0
Target Price
★ $44.69
N/A
AVG Volume (30 Days)
★ 291.0K
35.2K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
★ 11.11%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $38,419,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.72
$7.10
52 Week High
$43.85
$8.75

Technical Indicators

Market Signals
Indicator
STRO
GLQ
Relative Strength Index (RSI) 35.40 30.61
Support Level $8.11 N/A
Resistance Level $10.77 $7.76
Average True Range (ATR) 0.85 0.17
MACD 0.14 -0.04
Stochastic Oscillator 17.01 5.56

Price Performance

Historical Comparison
STRO
GLQ

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest

Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.

Share on Social Networks: